Corporate Presentation

Obesity Survodutide In a 16-week Phase 2 trial in T2DM, survodutide effectively reduced HbA1c and body weight Change in HbA1c Change body weight Mean (SE) absolute change (%) 0 -0.5- -1.0 -1.5 -2.0 -2.5 0 HHII T + H-0.25% HHHHH T F I -1.47% -1.88% LO 5 8 Weeks 12 16 17 End of treatment Placebo Survodutide 1.8 mg QW Survodutide 0.3 mg QW Survodutide 2.7 mg QW Survodutide 0.9 mg QW Survodutide 1.2 mg BIW aThe semaglutide arm was open-label. Mean (SE) relative change (%) 0 -2 + -6 -8 ZEAL& ZEALAND PHARMA Boehringer Ingelheim -1.20% T ++ ЕНЕ НА НЕЧ HHHHHH H I -5.40% -8.95% -10 T T T 0 2 3 4 5 6 7 8 Weeks 12 1617 End of treatment Survodutide 1.8 mg BIW Semaglutidea 1.0 mg QW The safety and tolerability profile was as expected and in line with increasing doses of GLP-1R agonists Body weight at baseline was 93.0-100.1 kg and HbA1c at baseline was 7.9-8.2%. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Sources: Figures adapted from Rosenstock. Presentation at ObesityWeek, November 1-4, 2022, San Diego, CA. BIW=twice-weekly; GLP-1R-glucagon-like peptide-1 receptor; HbA1c=hemoglobin A1c; QW-once-weekly; SE-standard error; T2DM-type 2 diabetes mellitus. 25 45

View entire presentation